Health Catalyst general counsel sells 99,478 shares

Available on EDGAR 11/13/2026 - 04:42 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:42 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) General Counsel Benjamin Landry reported direct sales of 70,000 common shares on November 11, 2026, at $1.4289 per share and 29,478 shares on November 12, 2026, at $1.3892 per share. Across both transactions, the reported sales totaled 99,478 shares.

Insider Trade Summary 10b5-1

Net Seller: 99,478 shares

Net Sell 2 txns

Insider Landry Benjamin

Role General Counsel

Sold 99,478 shs ($141K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	29,478	$1.3892	$41K
Sale	Common Stock F1	70,000	$1.4289	$100K

Holdings After Transaction: Common Stock — 251,894 shares (Direct)

Footnotes (1)

1. F1. The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on August 12th, 2026 in accordance with Rule 10b5-1.

Key Figures

Shares sold on November 11, 2026: 70,000 shares Sale price on November 11, 2026: $1.4289 per share Shares sold on November 12, 2026: 29,478 shares +2 more

5 metrics

Shares sold on November 11, 2026 70,000 shares Direct sale by Benjamin Landry

Sale price on November 11, 2026 $1.4289 per share Direct sale by Benjamin Landry

Shares sold on November 12, 2026 29,478 shares Direct sale by Benjamin Landry

Sale price on November 12, 2026 $1.3892 per share Direct sale by Benjamin Landry

Total shares sold 99,478 shares Across the reported transactions

Key Terms

Rule 10b5-1

1 terms

Rule 10b5-1 regulatory

"written trading plan adopted August 12, 2026"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HCAT shares did General Counsel Benjamin Landry sell, and at what prices?

Benjamin Landry sold 70,000 shares on November 11, 2026, at $1.4289 per share and 29,478 shares on November 12, 2026, at $1.3892 per share.

Were Benjamin Landry’s HCAT sales made under a trading plan?

Yes. The sales were made pursuant to a written Rule 10b5-1 trading plan adopted August 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Landry Benjamin

(Last) (First) (Middle)

10897 S. RIVER FRONT PARKWAY, #300

(Street)

SOUTH JORDAN UTAH 84095

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2026		S(1)		70,000	D	$1.4289	281,372	D
Common Stock	11/12/2026		S(1)		29,478	D	$1.3892	251,894	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on August 12th, 2026 in accordance with Rule 10b5-1.

Remarks:

	/s/ Benjamin Landry	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)